Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route

Infection and Immunity

Volumn 80, Issue 12, 2012, Pages 4133-4142

  Al Saleem, Fetweh H ^a,e   Ancharski, Denise M ^a   Joshi, Suresh G ^b   Elias, M ^a,b,e   Singh, Ajay ^c   Nasser, Zidoon ^d   Simpson, Lance L ^a,e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN E; NEUROTOXIN;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXIC INHALATION; TRANSCYTOSIS;

ABSORPTION; ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL TRANSPORT; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; MICE; RABBITS; TRANSCYTOSIS;

EID: 84870827073     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00669-12     Document Type: Article

References (36)

1. Ahsan CR, Hajnoczky G, Maksymowych AB, Simpson LL. 2005. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 315:1028-1035.
2. Al-Saleem FH, et al. 2008. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J. Pharmacol. Exp. Ther. 326:856-863.
3. Caya JC, Agni R, Miller JE. 2004. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch. Pathol. Lab. Med. 128:653-662.
4. Chen F, Kuziemko GM, Stevens RC. 1998. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun. 66:2420-2425.
5. Dezfulian M, Bartlett JG. 1985. Kinetics of growth and toxigenicity of Clostridium botulinum in experimental wound botulism. Infect. Immun.49:452-454.
6. Dolman CE, Iida H. 1963. Type E botulism: its epidemiology, prevention and specific treatment. Can. J. Public Health 54:293-308.
7. Fujinaga Y. 2006. Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J. Biochem.140:155-160.
8. Fujinaga Y, et al. 2000. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 467:179-183.
9. Fujinaga Y, et al. 1997. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology 143:3841-3847.
10. Gordon RJ, Lowy FD. 2005. Bacterial infections in drug users. N. Engl. J.Med. 353:1945-1954.
11. Hansen N, Tolo V. 1979. Wound botulism complicating an open fracture. J. Bone Joint Surg. Am. 61:312-314.
12. Hasegawa K, et al. 2007. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J. Biol. Chem.282:24777-24783.
13. Holzer VE. 1962. Botulismus durch inhalation. Med. Klin. 57:1735-1738.
14. Isacsohn M, Cohen A, Steiner A, Rosenberg P, Rudensky B. 1985.Botulism intoxication after surgery in the gut. Isr. J. Med. Sci. 21:150-153.
15. Jin Y, Takegahara Y, Sugawara Y, Matsumura T, Fujinaga Y. 2009.Disruption of the epithelial barrier by botulinum haemagglutinin (HA)proteins- differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology 155:35-45.
16. Joshi A, et al. 2011. Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. Neuroscience 179:208-222.
17. Kalka-Moll WM, Aurbach U, Schaumann R, Schwarz R, Seifert H.2007. Wound botulism in injection drug users. Emerg. Infect. Dis. 13:942-943.
18. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
19. MacDonald KL, Rutherford GW, Friedman SM. 1985. Botulism and botulism-like illness in chronic drug abusers. Ann. Intern. Med. 102:616-618.
20. Maksymowych AB, et al. 1999. Pure botulinum toxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 67:4708-4712.
21. Maksymowych AB, Simpson LL. 1998. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem. 273:21950-21957.
22. Maksymowych AB, Simpson LL. 2004. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 310:633-641.
23. Matsumura T, et al. 2008. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell. Microbiol. 10:355-364.
24. Mitchell PA, Pons PT. 2001. Wound botulism associated with black tar heroin and lower extremity cellulitis. J. Emerg. Med. 20:371-375.
25. Park JB, Simpson LL. 2003. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect. Immun.71:1147-1154.
26. Popoff MR. 1995. Ecology of neurotoxigenic strains of clostridia. Curr. Top. Microbiol. Immunol. 195:1-29.
27. Raffestin S, Marvaud JC, Cerrato R, Dupuy B, Popoff MR. 2004.Organization and regulation of the neurotoxin genes in Clostridium botulinum and Clostridium tetani. Anaerobe 10:93-100.
28. Raihana RR, et al. 2009. Analysis of the properties of neutralizing monoclonal antibodies against the hemagglutinating Encephalomyelitis virus and inhibition of HEV infection by specific MAb. J. Vet. Med. Sci. 71:447-452.
29. Ravichandran E, et al. 2007. A trivalent vaccine against botulinum toxin (serotypes A, B, and E) that can be administered by the mucosal route. Infect. Immun. 75:3043-3054.
30. Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiological review. Ann. Intern. Med. 129:221-228.
31. Simpson LL. 2004. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44:167-193.
32. Simpson LL. 2009. Botulinum toxin, p 891-917. In Barrett ADT, Stanberry L (ed), Vaccines for biodefense and emerging and neglected diseases. Elsevier Inc., San Diego, CA.
33. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. 2004. Foodborne botulism in the United States, 1990-2000. Emerg. Infect. Dis. 10:1606-1611.
34. Werner SB, Passaro D, McGee J, Schechter R, Vugia DJ. 2000. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin. Infect. Dis. 31:1018-1024.
35. Whittaker RL, Gilbertson RB, Garrett AS. 1964. Botulism, type E. Ann. Intern. Med. 448-454.
36. Zhou Y, Paturi S, Lindo P, Shoesmith SM, Singh BR. 2007. Cloning, expression, purification, and characterization of biologically active recombinant hemagglutinin-33 type A botulinum neurotoxin associated protein. Protein J. 26:29-37.